Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region

Status Completed

Clinical Trial Summary

Despite the implementation of a national strategy to prevent the transmission of the human immunodeficiency virus (HIV) combining prevention campaigns, condom use, early detection of HIV infections and recommendations for treatment as soon as possible, the number of new HIV-infected patients per year in France does not decrease. New HIV prevention strategies are therefore clearly needed. Since 2009, several studies have shown that tenofovir disoproxil fumarate and emtricitabine (TDF/FTC), an antiretroviral therapy combining two nucleoside reverse transcriptase inhibitors used for the treatment of patients seropositive for HIV, has preventive activity on HIV transmission. These results enabled the TDF/FTC to obtain in France an extension of the marketing authorization in March 2017 for preexposure prophylaxis (PrEP) of HIV transmission among patients at high risk of contamination. Since the approval, many studies around the world investigate the use of PrEP in routine practice, highlighting its effectiveness in real life. These studies describe the population of patients who benefit from PrEP in order to adapt their multidisciplinary care but also track the transmission of other sexually transmitted infections to prevent their emergence, given the observed decline in condom use. However, these studies are limited to big cities while PrEP is accessible in all territories. The Rhône-Alpes region is one of the three French regions that has been the most involved in the implementation of PrEP, one year after the FTC/TDF approval in France. Given the geographical position of the investigators, both in province and close to Switzerland, where the FTC/TDF is not authorized for PrEP, and the non-university nature of five of the six involved hospitals, the investigators would like to determine the profile of patients consulting in this region to benefit from PrEP. This analysis will also determine if the population at risk of the "Alpine Arc" region is similar to that observed in the other cohorts in order to adapt patient care.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03995862
Study type	Observational
Source	Centre Hospitalier Annecy Genevois
Contact
Status	Completed
Phase
Start date	May 29, 2019
Completion date	April 6, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06162897` - Case Management Dyad	N/A
Active, not recruiting	`NCT04064567` - Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK	N/A
Completed	`NCT03805451` - Life Steps for PrEP for Youth	N/A
Not yet recruiting	`NCT06046079` - Predictors of Health Service Utilizations Among Key Population in Washington DC
Recruiting	`NCT05929521` - Centering Those Engaged in Transactional Sex: A PrEP Innovation for Getting To Zero	Early Phase 1
Recruiting	`NCT05165745` - Stick2PrEP Cisgender Women and Trans Individuals	N/A
Completed	`NCT03177512` - LYNX: A Novel Mobile App to Support Linkage to HIV/STI Testing PrEP for Young Men Who Have Sex With Men	N/A
Completed	`NCT04205487` - PrEP Readiness Interventions for Supporting Motivation	N/A
Completed	`NCT03965221` - Comparison of Men's Prevention Apps to Research Efficacy	N/A
Completed	`NCT05417620` - Le Kip Kip: A Campaign to Change Social Norms and Build Sustainable Demand for PrEP Among Women in South Africa	N/A
Completed	`NCT03226873` - Peer Outreach and Navigation Intervention to Increase PrEP Uptake Among Women at High Risk for HIV	N/A
Completed	`NCT03493555` - Optimizing PrEP Adherence for Young Men Who Have Sex With Men	N/A
Recruiting	`NCT05728034` - Information Seeking About Pre-exposure Prophylaxis	N/A
Completed	`NCT03729570` - Electronic Pre-exposure Prophylaxis (PrEP) Initiation and Maintenance Home Care System	N/A
Completed	`NCT04248790` - Design and Development of a Mobile App to Improve Adherence to Pre-exposure Prophylaxis in Men Who Have Sex With Men	N/A
Recruiting	`NCT05614492` - Development and Evaluation of a PrEP Decision Aid for Women Seeking Domestic Violence Services in Baltimore	Phase 2/Phase 3
Completed	`NCT04712994` - PrEPARE: PrEP in Pregnancy, Accelerating Reach and Efficiency	N/A
Recruiting	`NCT05856942` - Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program	N/A
Recruiting	`NCT06296602` - Screening Anal HPV Colonization in Men Sex Men Using Pre-exposure Prophylaxis for HIV (ANAPreP'HPV)	N/A
Withdrawn	`NCT04990583` - mHealth Facilitated Intervention to Improve HIV Pre-Exposure Prophylaxis Adherence	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region — PrEP2A

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms